Apellis Pharmaceuticals (NASDAQ:APLS) Releases Earnings Results, Misses Estimates By $0.14 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) announced its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14), Briefing.com reports. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the business earned ($1.17) EPS. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis.

Apellis Pharmaceuticals Stock Performance

APLS traded up $0.32 during trading on Wednesday, hitting $28.40. The stock had a trading volume of 1,796,003 shares, compared to its average volume of 1,771,285. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. The company has a 50 day moving average price of $31.58 and a 200-day moving average price of $37.26. Apellis Pharmaceuticals has a one year low of $24.34 and a one year high of $73.80. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -10.28 and a beta of 0.87.

Analysts Set New Price Targets

A number of research analysts have weighed in on APLS shares. Wedbush raised their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Oppenheimer decreased their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday. Piper Sandler dropped their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday. Evercore ISI raised shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Finally, Mizuho lowered their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. Six research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.24.

Insiders Place Their Bets

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).